Latest & greatest articles for Mycosis Fungoides

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Mycosis Fungoides or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Mycosis Fungoides and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Mycosis Fungoides

1. Corneal infiltration and xanthoma formation in mycosis fungoides (PubMed)

Corneal infiltration and xanthoma formation in mycosis fungoides To report a case of corneal infiltration and xanthoma formation in mycosis fungoides (cutaneous T-cell lymphoma).A middle aged Japanese man with mycosis fungoides (MF) involving the face was referred to Ophthalmology for evaluation of unilateral, painless conjunctival injection. Biopsy of the conjunctiva revealed a malignant T cell population consistent with MF tumor invasion. Years later, he returned following several episodes

Full Text available with Trip Pro

2018 American journal of ophthalmology case reports

2. Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma

Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/CHMP/13156/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) purified HPRT hypoxanthine-guanine phosphoribosyltransferase IARC International Agency for Research on Cancer IC50 half-maximal inhibitory concentration ICH International Conference on Harmonisation IID Inactive Ingredient Database i.p. intraperitoneal i.v. intravenous IR InfraredKF Karl Fischer titration LD50 median lethal dose MDA malondialdehyde MDEA N-methyldiethanolamine MF mycosis fungoides MF-type CTC mycosis fungoides-type cutaneous T-cell lymphoma MNNG N-methyl-N´-nitro-N-nitrosoguanidine MTD

2017 European Medicines Agency - EPARs

3. Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis (PubMed)

Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis Mycosis fungoides (MF) is a significant diagnostic challenge; it has various differential diagnosis especially at an early stage. Our aim was to describe mimics of MF clinically and histologically, and to define significant diagnostic criteria of the disease.This was a retro-prospective cohort of 370 patients in whom the diagnosis of MF was suspected clinically.MF was histologically

Full Text available with Trip Pro

2017 International journal of women's dermatology

5. Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness

Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Published on: September 30, 2015 Project (...) Number: RB0915-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of extracorporeal photopheresis (ECP) for the management of Sezary Syndrome or Mycosis fungoides? What is the cost-effectiveness of ECP for the management of Sezary Syndrome or Mycosis fungoides? Key Message One systematic review, four non-randomized studies, and one economic evaluation were identified regarding extracorporeal

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Phototherapy for early-stage mycosis fungoides

Phototherapy for early-stage mycosis fungoides Phototherapy for early-stage mycosis fungoides Phototherapy for early-stage mycosis fungoides Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Phototherapy for early-stage mycosis fungoides. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication Dates. 2012 Authors' conclusions Cutaneous T-cell lymphomas (...) (CTCL) are a heterogeneous group of non-Hodgkin's lymphomas characterized by their initial manifestation in the skin. Mycosis fungoides (MF), which evolves from scaly skin patches and plaques, is the most common form of CTCL affecting approximately 65% of cases. The incidence of MF in the United States has been estimated at 6 cases per 1 million individuals with a male predominance. MF is broadly divided into early- and advanced-stage disease and classified into four clinical stages (I-IV). Skin

2012 Health Technology Assessment (HTA) Database.

7. Mycosis fungoides and Sézary syndrome. (PubMed)

Mycosis fungoides and Sézary syndrome. Mycosis fungoides and Sézary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous group of neoplasms that affect the skin as a primary site. Although the aetiologies of mycosis fungoides and Sézary syndrome are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases. Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely (...) increasing toxic effects in advanced disease that is otherwise difficult to treat. Although present treatment strategies are generally not curative, there is hope that experimental treatments, particularly immunotherapy, might eventually reverse or suppress the abnormalities of mycosis fungoides and Sézary syndrome to the point at which they become non-life-threatening, chronic diseases.

2008 Lancet

8. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome) Bunn P A, Hoffman S J, Norris D, Golitz L E, Aeling J L Authors' objectives To review recent studies of systemic therapy for mycosis fungoides and the Sezary syndrome. Searching MEDLINE was searched from 1988 to 1994 (...) . Participants included in the review Patients with mycosis fungoides or the Sezary syndrome. Outcomes assessed in the review The objective response to treatment (complete response or partial response) was assessed. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many of the authors performed the selection. Assessment of study quality The authors do not state that they assessed validity. Data extraction The data were

1994 DARE.

9. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. (PubMed)

A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. Mycosis fungoides is a T-cell lymphoma that arises in the skin and progresses at highly variable rates. Nonradomized studies have suggested that early aggressive therapy may improve the prognosis in this usually fatal disease. We studied 103 patients with mycosis fungoides, who, after complete staging, were randomly assigned to receive either (...) leukemia. Patients receiving combined therapy had a significantly higher rate of complete response, documented by biopsy, than patients receiving conservative therapy (38 percent vs. 18 percent; P = 0.032). After a median follow-up of 75 months, however, there was no significant difference between the treatment groups in disease-free or overall survival. We conclude that early aggressive therapy with radiation and chemotherapy does not improve the prognosis for patients with mycosis fungoides

1989 NEJM